MedPath

Mycophenolic acid

Generic Name
Mycophenolic acid
Brand Names
Myfortic
Drug Type
Small Molecule
Chemical Formula
C17H20O6
CAS Number
24280-93-1
Unique Ingredient Identifier
HU9DX48N0T
Background

Mycophenolic acid is a potent immunosuppressant agent that inhibits de novo purine biosynthesis. It was derived from Penicillium stoloniferum, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. This regimen can be used in place of the older anti-proliferative azathioprine due to its stronger immunosuppressive potency. However, mycophenolic acid treatment is more expensive and requires therapeutic drug monitoring to optimize efficacy and minimize toxicity. Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until it reaches the small intestine. Mycophenolate mofetil, a prodrug of mycophenolic acid, is also prescribed to transplant recipients to prevent organ rejection.

Indication

Mycophenolic acid is an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. Mycophenolic acid is used in combination with cyclosporine and corticosteroids.

Associated Conditions
Kidney Transplant Rejection

Outcome Study of Conventional Steroids Vs. Steroids Combined with Mycopehnolate in Newly Diagnosed Immune Thrombocytopenia Purpura.

Phase 3
Completed
Conditions
Immune Thrombocytopenia Purpura
Interventions
First Posted Date
2024-03-01
Last Posted Date
2024-11-06
Lead Sponsor
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Target Recruit Count
118
Registration Number
NCT06288932
Locations
🇵🇰

National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Sindh, Pakistan

Graves' Disease Remission Study: MycoMeth Combo

Phase 2
Recruiting
Conditions
Graves' Disease
Interventions
Drug: methimazole, oral, 10mg
First Posted Date
2023-10-05
Last Posted Date
2024-02-28
Lead Sponsor
The First Affiliated Hospital of Xiamen University
Target Recruit Count
205
Registration Number
NCT06068179
Locations
🇨🇳

Xiao Fangsen, Xiamen, Fujian, China

MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients

Phase 4
Recruiting
Conditions
Kidney Transplant
Interventions
First Posted Date
2023-09-21
Last Posted Date
2024-12-16
Lead Sponsor
Chong Kun Dang Pharmaceutical
Target Recruit Count
158
Registration Number
NCT06044493
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

Phase 4
Not yet recruiting
Conditions
Kidney Transplant Rejection
Interventions
First Posted Date
2023-05-24
Last Posted Date
2023-05-24
Lead Sponsor
Zhishui Chen
Target Recruit Count
270
Registration Number
NCT05872568

Long-term Benefit of MPA in Liver Transplantation

Recruiting
Conditions
Liver Transplant Rejection
Immunosuppressant Adverse Reaction
Interventions
First Posted Date
2023-02-01
Last Posted Date
2023-02-01
Lead Sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Target Recruit Count
500
Registration Number
NCT05707520
Locations
🇨🇳

Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis

Phase 4
Recruiting
Conditions
Hypersensitivity Pneumonitis
Interventions
First Posted Date
2022-11-23
Last Posted Date
2022-11-30
Lead Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Target Recruit Count
144
Registration Number
NCT05626387
Locations
🇮🇳

Postgraduate Institute of Medical Education and Research, Chandigarh, India

Immunosuppressive Treatment in Chronic Virus-Negative Inflammatory Cardiomyopathy

First Posted Date
2022-10-06
Last Posted Date
2024-08-16
Lead Sponsor
LMU Klinikum
Target Recruit Count
130
Registration Number
NCT05570409
Locations
🇩🇪

Kerckhoff-Klinik GmbH, Bad Nauheim, Germany

🇩🇪

Charité - University Hospital Berlin, Berlin, Germany

🇩🇪

UHF- Universitäres Herz- und Gefässzentrum, Frankfurt, Germany

and more 11 locations

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Phase 1
Recruiting
Conditions
Peripheral Blood Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation
Interventions
First Posted Date
2022-06-29
Last Posted Date
2025-04-15
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
260
Registration Number
NCT05436418
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

🇺🇸

City of Hope, Duarte, California, United States

Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

Phase 2
Recruiting
Conditions
Systemic Lupus Erythematosus
Interventions
First Posted Date
2022-04-01
Last Posted Date
2024-01-19
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
120
Registration Number
NCT05306873
Locations
🇺🇸

UCLA Medical Center: Division of Rheumatology, Los Angeles, California, United States

🇺🇸

Yale University School of Medicine: Rheumatology, Allergy & Immunology, New Haven, Connecticut, United States

🇺🇸

Emory University School of Medicine: Division of Rheumatology, Atlanta, Georgia, United States

and more 8 locations

A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)

Phase 4
Conditions
Pemphigus Vulgaris
Interventions
First Posted Date
2022-03-31
Last Posted Date
2022-03-31
Lead Sponsor
Tongji Hospital
Target Recruit Count
60
Registration Number
NCT05303272
Locations
🇨🇳

Tongji Hospital, Wuhan, Hubei, China

© Copyright 2025. All Rights Reserved by MedPath